“We are encouraged by the data from our Phase 1/2 clinical trial using ETBX-011 for the treatment of mCRC patients and plan to initiate a larger randomized Phase 2b trial later this year to extend the evaluation of our vector gene delivery platform. Furthermore, the killer T-cell induction in this patient population certainly deserves continued study and an attempt to correlate these effects with mCRC patient anti-cancer responses. The overall survival of the 32 mCRC patients in the current Phase 1/2 trial compares favorably with other published trials at this stage,” stated
Etubics Phase 1/2 mCRC trial was funded primarily through support from the
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.